SciSparc Ltd.
SPRCHealthcare|Biotechnology|IL
$0.42
-0.01 (-2.45%)
Cash / Share
$8.01
Financials
Financial Snapshot
Market Cap
$243.2K
Enterprise Value
-$1.5M
Revenue (TTM)
$1.6M
Net Income (TTM)
-$20.4M
Cash & Investments
$4.4M
Net Cash
$1.8M
Free Cash Flow (TTM)
-$10.6M
Operating CF (TTM)
-$10.6M
Debt/Equity
0.68
Cash Runway & Burn Rate
Cash on Hand
$4.4M
Quarterly Burn
$2.7M
Monthly Burn
$883.8K
Est. Runway
~1.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $675.4K | $9.2M | $1.5M | $870.0K | $1.9M | $6.9M | $3.6M | $5.1M | $2.1M | $4.6M | $4.4M | |
| Operating Cash Flow | -$1.5M | -$4.6M | -$7.1M | -$4.7M | -$4.3M | -$5.1M | -$7.9M | -$5.9M | -$5.1M | -$4.1M | -$10.6M | |
| Free Cash Flow | -$1.5M | -$4.6M | -$7.1M | -$4.7M | -$4.3M | -$5.1M | -$12.8M | -$5.9M | -$5.1M | -$4.1M | -$10.6M | |
| Capital Expenditure | -$4.2K | -$44.0K | -$17.0K | -$1.0K | $0.00 | -$35.0K | -$4.9M | $0.00 | $0.00 | $0.00 | $1.0K | |
| Financing Cash Flow | $563.9K | $13.2M | $1.5M | $2.8M | $5.4M | $10.1M | $11.7M | $5.5M | $6.2M | $8.6M | $17.8M |
R&D Spending
R&D (TTM)
$4.6M
R&D Intensity
289.3%
R&D Growth vs Prior
+112.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $487.0K | $838.0K | $498.0K | $550.0K | $1.1M | $1.3M | $2.9M | $1.3M | $856.0K | $1.6M | |
| R&D Expense | $738.8K | $2.0M | $2.7M | $1.6M | $649.0K | $2.0M | $2.8M | $1.6M | $1.8M | $2.2M | $4.6M | |
| R&D % of Revenue | — | 414.2% | 323.4% | 329.1% | 118.0% | 186.2% | 208.1% | 57.0% | 139.0% | 255.4% | 289.3% | |
| SG&A | $1.3M | $3.7M | $5.8M | $2.4M | $1.7M | $3.6M | $6.3M | $6.1M | $5.8M | $5.4M | $13.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $487.0K | $838.0K | $498.0K | $550.0K | $1.1M | $1.3M | $2.9M | $1.3M | $856.0K | $1.6M | |
| Cost of Revenue | $0.00 | $5.0K | $147.0K | $179.0K | $164.0K | $33.0K | $322.0K | $683.0K | $800.0K | $225.0K | $965.0K | |
| Gross Profit | $0.00 | $482.0K | $691.0K | $319.0K | $386.0K | $1.0M | $1.0M | $2.2M | $506.0K | $631.0K | $641.0K | |
| R&D | $738.8K | $2.0M | $2.7M | $1.6M | $649.0K | $2.0M | $2.8M | $1.6M | $1.8M | $2.2M | $4.6M | |
| SG&A | $1.3M | $3.7M | $5.8M | $2.4M | $1.7M | $3.6M | $6.3M | $6.1M | $5.8M | $5.4M | $13.2M | |
| Operating Income | -$2.0M | -$5.8M | -$9.7M | -$4.1M | -$3.3M | -$5.8M | -$7.4M | -$5.8M | -$7.3M | -$8.7M | -$24.5M | |
| Interest Expense | $1.3K | $5.0K | $123.0K | $568.0K | $25.0K | $12.0K | $36.0K | $9.0K | $30.0K | $11.0K | $8.2M | |
| Pretax Income | -$2.0M | -$6.2M | -$9.0M | -$4.5M | -$3.5M | -$5.8M | -$2.6M | -$5.9M | -$7.5M | -$12.6M | -$22.4M | |
| Net Income | -$2.0M | -$6.2M | -$8.5M | -$5.4M | -$3.5M | -$5.8M | -$2.6M | -$5.1M | -$6.3M | -$12.2M | -$20.4M | |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3311.10 | -666.90 | -649.35 | -9.72 | -882.64 | -253.82 | |
| EBITDA | -$2.0M | -$5.7M | -$6.9M | -$3.7M | -$2.4M | -$5.7M | -$2.4M | -$5.3M | -$7.0M | -$12.3M | -$17.0M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.10 | 0.23 | 0.65 | 13.80 | 0.55 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $675.4K | $9.2M | $1.5M | $870.0K | $1.9M | $6.9M | $3.6M | $2.1M | $1.5M | $4.6M | $4.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.0M | $517.0K | $0.00 | $0.00 | |
| Total Current Assets | $803.8K | $9.5M | $2.4M | $955.0K | $2.5M | $9.8M | $4.5M | $6.4M | $7.5M | $5.4M | $5.6M | |
| Total Assets | $1.2M | $9.6M | $4.6M | $1.2M | $2.6M | $9.9M | $10.6M | $11.2M | $10.3M | $7.6M | $18.5M | |
| Total Current Liabilities | $672.0K | $1.2M | $4.5M | $1.0M | $1.1M | $1.8M | $4.2M | $1.6M | $1.4M | $2.3M | $6.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $672.0K | $1.2M | $4.5M | $1.1M | $1.1M | $1.8M | $4.2M | $1.6M | $1.4M | $2.5M | $7.2M | |
| Stockholders' Equity | $572.7K | $8.1M | $185.0K | $14.0K | $1.4M | $8.1M | $6.4M | $7.6M | $8.2M | $4.2M | $3.9M | |
| Retained Earnings | -$31.5M | -$38.4M | -$46.9M | -$51.7M | -$55.2M | -$61.0M | -$63.6M | -$68.7M | -$75.0M | -$87.2M | -$92.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.5M | -$4.6M | -$7.1M | -$4.7M | -$4.3M | -$5.1M | -$7.9M | -$5.9M | -$5.1M | -$4.1M | -$10.6M | |
| Capital Expenditure | -$4.2K | -$44.0K | -$17.0K | -$1.0K | $0.00 | -$35.0K | -$4.9M | $0.00 | $0.00 | $0.00 | $1.0K | |
| Free Cash Flow | -$1.5M | -$4.6M | -$7.1M | -$4.7M | -$4.3M | -$5.1M | -$12.8M | -$5.9M | -$5.1M | -$4.1M | -$10.6M | |
| Investing Cash Flow | -$4.4K | -$53.0K | -$2.1M | $1.3M | $24.0K | -$70.0K | -$7.1M | -$1.1M | -$1.6M | -$1.4M | -$3.0M | |
| Financing Cash Flow | $563.9K | $13.2M | $1.5M | $2.8M | $5.4M | $10.1M | $11.7M | $5.5M | $6.2M | $8.6M | $17.8M | |
| Issuance of Stock | $914.1K | $13.2M | $0.00 | $2.2M | $2.6M | $7.7M | $9.0M | $5.6M | $6.3M | $4.1M | $15.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $1.6M | -$47.0K | $224.0K | -$207.0K | -$70.0K | -$47.0K | -$54.0K | $4.5M | $2.2M | |
| Stock Based Comp. | $326.5K | $862.0K | $604.0K | $553.0K | $91.0K | $43.0K | $897.0K | $196.0K | $569.0K | $1.2M | $1.7M | |
| Net Change in Cash | -$919.8K | $8.5M | -$7.7M | -$615.0K | $1.1M | $4.9M | -$3.3M | -$1.5M | -$536.0K | $3.1M | $4.2M |
Dilution Tracker
Shares outstanding grew 15619.6% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+15619.6%
Stock Issuance (TTM)
$15.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.10 | 0.23 | 0.65 | 13.80 | 0.55 | |
| Change vs Prior % | — | — | — | — | — | — | 11.4% | 131.8% | 185.5% | 2031.9% | -96.0% | |
| Stock Issuance | $914.1K | $13.2M | $0.00 | $2.2M | $2.6M | $7.7M | $9.0M | $5.6M | $6.3M | $4.1M | $15.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $326.5K | $862.0K | $604.0K | $553.0K | $91.0K | $43.0K | $897.0K | $196.0K | $569.0K | $1.2M | $1.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 99.0% | 82.5% | 64.1% | 70.2% | 96.9% | 76.1% | 76.3% | 38.7% | 73.7% | 39.9% | |
| Operating Margin % | — | -1181.5% | -1159.2% | -824.9% | -598.7% | -539.6% | -547.9% | -200.5% | -560.2% | -1022.1% | -1524.2% | |
| Net Margin % | — | -1282.1% | -1017.1% | -1076.7% | -637.6% | -542.7% | -192.4% | -177.9% | -481.2% | -1422.8% | -1269.7% | |
| EBITDA Margin % | — | -1180.3% | -827.4% | -749.4% | -434.0% | -537.3% | -174.8% | -184.6% | -534.0% | -1439.1% | -1057.2% | |
| FCF Margin % | — | -949.3% | -853.1% | -943.2% | -783.1% | -476.7% | -949.2% | -204.5% | -390.8% | -483.3% | -660.3% | |
| ROE % | -347.5% | -76.8% | -4607.0% | -38300.0% | -245.2% | -71.3% | -40.2% | -67.3% | -77.1% | -287.3% | -200.9% | |
| ROA % | -159.9% | -65.3% | -186.9% | -464.6% | -136.9% | -58.5% | -24.4% | -45.8% | -60.7% | -159.8% | -44.5% | |
| ROIC % | -347.5% | -68.6% | -788.3% | -799.2% | -203.5% | -66.7% | -114.0% | -59.7% | -81.3% | -152.6% | -30.3% | |
| R&D / Revenue % | — | 414.2% | 323.4% | 329.1% | 118.0% | 186.2% | 208.1% | 57.0% | 139.0% | 255.4% | 289.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 72.1% | -40.6% | 10.4% | 94.4% | 26.0% | 113.7% | -54.6% | -34.5% | |
| Gross Profit | 100.0% | 0.0% | 43.4% | -53.8% | 21.0% | 168.4% | -1.1% | 114.2% | -77.0% | 24.7% | |
| Operating Income | 21.7% | -188.1% | -68.8% | 57.7% | 19.8% | -75.2% | -27.9% | 21.8% | -26.7% | -19.6% | |
| Net Income | 21.3% | -213.7% | -36.5% | 37.1% | 34.6% | -65.4% | 55.3% | -97.6% | -22.7% | -93.8% | |
| EPS (Diluted) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 79.9% | 2.6% | 98.5% | -8980.7% | |
| Operating Cash Flow | -11.9% | -209.6% | -55.8% | 34.2% | 8.3% | -17.5% | -56.4% | 25.6% | 13.3% | 18.9% | |
| Free Cash Flow | -12.1% | -211.7% | -54.6% | 34.3% | 8.3% | -18.3% | -150.9% | 54.0% | 13.3% | 18.9% | |
| R&D Expense | 209.8% | 173.0% | 34.4% | -39.5% | -60.4% | 206.6% | 40.9% | -41.5% | 10.6% | 20.4% | |
| SG&A Expense | 60.5% | 189.5% | 55.5% | -58.8% | -28.2% | 111.8% | 72.1% | -2.2% | -5.3% | -6.3% | |
| Total Assets | -25.3% | 668.5% | -52.3% | -74.7% | 121.9% | 287.2% | 6.9% | 5.4% | -7.5% | -26.3% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -28.7% | -26.8% | -71.6% | -97.3% | |
| Debt | 0.0% | 0.0% | 0.0% | -72.9% | -7.0% | 8.4% | -94.6% | 181.5% | -39.5% | 695.7% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 11.4% | 131.8% | 185.5% | 2031.9% |
Valuation
P/E (TTM)At Loss
P/S0.36
10Y Low / Med / High33.72 / 197.30 / 2503.49
P/B0.06
10Y Low / Med / High5.40 / 39.84 / 328.74
EV/EBITDA0.35
10Y Low / Med / High0.10 / 0.62 / 1.60
EV/Revenue-2.23
10Y Low / Med / High0.43 / 192.37 / 2497.53
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$8.01
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -46.42 | -28.03 | -8.17 | -7.00 | -0.01 | -0.01 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2503.49 | 268.04 | 63.17 | 33.72 | 197.30 | 0.36 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 328.74 | 55.98 | 23.89 | 5.40 | 39.84 | 0.06 | |
| EV/EBITDA | 0.34 | 1.60 | -0.05 | 0.10 | 0.62 | -464.81 | -151.80 | -33.85 | -6.10 | -13.37 | 0.35 | |
| EV/Revenue | 0.00 | -18.88 | 0.43 | -0.74 | -2.69 | 2497.53 | 265.40 | 62.48 | 32.57 | 192.37 | -2.23 |
Analyst Estimates & Quality
Altman Z-Score
-7.80
Distress
Piotroski F-Score
3
Weak